29 September 2023 Viralgen Vector Core and Elpida Therapeutics partner to manufacture gene therapy medicines for anticipated Spastic Paraplegia 50 (SPG50) and Charcot-Marie-Tooth disease type 4J (CMT4J) clinical trials 0 minute read Pharma/Biotech By Cate Swannell Previous Post Next Post